Joseph Martel, MD
Ophthalmology · Rancho Cordova, CANPI 1063439776
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,400 of the $16,322 with a category attached, or 63.7%. Bausch Health US, LLC accounts for 63.7% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2020 at $10,750 and has fallen 91.9% since, to $876 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 313 payments — averaging $52.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch Health US, LLC$10K
- AbbVie$717
- Alcon$711
- Bausch & Lomb, A Division Of Bausch Health US, LLC$660
- Bausch & Lomb Americas Inc.$603
- Glaukos Corporation$507
- plus $3K from 23 others
Across 356 payments — averaging $6326.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$503K
- Novartis$440K
- Bausch Health US, LLC$377K
- Oyster Point Pharma, Inc.$365K
- Kala Pharmaceuticals, Inc.$200K
- Glaukos Corporation$116K
- plus $252K from 5 others
What the payments were for
- Consulting fees$10,40064%
- Travel & lodging$2101%
- Food & beverage$5,68935%
- Entertainment$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch Health US, LLC | 1 | $10,400 |
| AbbVie(2 entities) | 45 | $717 |
| Alcon | 33 | $711 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 64 | $660 |
| Bausch & Lomb Americas Inc. | 51 | $603 |
| Glaukos Corporation | 13 | $507 |
| Oyster Point Pharma, Inc. | 12 | $432 |
| Novartis | 8 | $414 |
| Eyevance Pharmaceuticals LLC | 14 | $238 |
| Amgen(2 entities) | 11 | $237 |
| Aerie Pharmaceuticals, Inc. | 14 | $229 |
| Biotissue Holdings Inc. | 11 | $202 |
| Kala Pharmaceuticals, Inc. | 7 | $161 |
| Sight Sciences, Inc. | 3 | $111 |
| Sandoz | 1 | $105 |
| Sun Pharmaceutical Industries Inc. | 4 | $92 |
| Dompe US, Inc. | 3 | $87 |
| Genentech USA, Inc. | 3 | $69 |
| Harrow Eye, LLC | 2 | $65 |
| Mallinckrodt Hospital Products Inc. | 3 | $64 |
| Astellas Pharma US Inc | 2 | $38 |
| Apellis Pharmaceuticals, Inc. | 1 | $31 |
| Rayner Intraocular Lenses Limited | 1 | $30 |
| Thea Pharma Inc. | 1 | $25 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| Optos, Inc. | 1 | $23 |
| Carl Zeiss Meditec USA, Inc. | 1 | $17 |
| Tarsus Pharmaceuticals, Inc. | 1 | $16 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,322 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 162 | $79,884 |
| VyzultaLatanoprostene Bunod | 103 | $39,946 |
| RestasisCyclosporine | 24 | $33,884 |
| Prednisolone Acetate | 698 | $25,474 |
| RocklatanNetarsudil Mesylat/Latanoprost | 66 | $25,427 |
| Alphagan PBrimonidine Tartrate | 62 | $23,161 |
| ProlensaBromfenac Sodium | 68 | $23,003 |
| XiidraLifitegrast | 20 | $22,498 |
| Cyclosporine | 36 | $21,327 |
| Restasis MultidoseCyclosporine | 21 | $21,234 |
| Bromfenac Sodium | 88 | $16,531 |
| CombiganBrimonidine Tartrate/Timolol | 36 | $15,717 |
| Timolol Maleate | 202 | $14,291 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 68 | $14,210 |
| MoxifloxacinMoxifloxacin Hcl | 425 | $9,889 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Restasis Multidose, Combigan | $717 | $173,880305 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $603 | $62,444123 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $229 | $25,42766 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $660 | $23,00368 claims |
| AlconSimbrinza | $711 | $14,21068 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Rancho Cordova
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.